Clinical trial

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

NCT02991859

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-02-09

PhasePHASE2

Study timeline

Study start (actual)2017-02-09Date precision: day

Registry last updated2020-07-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

Fluticasone furoate (FF) Dry Powder InhalerDRUG

Fluticasone propionate (FP) Dry Powder InhalerDRUG

Budesonide (BUD) TurbuhalerDRUG

Placebo (ELLIPTA or DISKUS)DRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

BerlinGermany1 ManchesterUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02991859 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.